Lexicon Pharmaceuticals (NASDAQ:LXRX) Posts Earnings Results, Beats Estimates By $0.03 EPS

Lexicon Pharmaceuticals (NASDAQ:LXRX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03, FiscalAI reports. The business had revenue of $5.49 million during the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 52.90% and a negative net margin of 96.77%.

Here are the key takeaways from Lexicon Pharmaceuticals’ conference call:

• SONATA‑HCM (sotagliflozin) has surpassed 50% enrollment across 130+ sites and is on track to complete enrollment by mid‑2026 with top‑line results expected in Q1‑2027, representing a potential first‑in‑class HCM opportunity.
• Management expects to resubmit the NDA for Zynquista in type 1 diabetes in 2026 based on the investigator‑led Steno‑1 study, with a ~6‑month review and potential approval later in 2026 if patient exposure and DKA rates meet FDA criteria.
• Pilavapadin received a successful end‑of‑Phase‑2 meeting with the FDA (no objections to Phase‑3 design) and Lexicon is actively seeking a development partner for pivotal studies rather than self‑funding Phase 3.
• Early obesity program LX9851 triggered a $10M milestone from Novo Nordisk, development has been handed off to Novo, and up to $20M more in milestones are possible in 2026, signaling partner validation of the asset.
• Financially, operating expenses and net loss improved materially in 2025 and Lexicon raised >$100M of additional cash post‑year‑end, but year‑end cash was $125.2M and 2026 operating expense guidance is $100–110M, indicating ongoing financing and execution needs.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.64 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.63 and a current ratio of 5.64. The company has a market capitalization of $596.09 million, a price-to-earnings ratio of -8.63 and a beta of 0.94. The company’s 50 day simple moving average is $1.35 and its 200 day simple moving average is $1.33. Lexicon Pharmaceuticals has a 1 year low of $0.32 and a 1 year high of $1.83.

Insider Activity at Lexicon Pharmaceuticals

In other Lexicon Pharmaceuticals news, Director Raymond Debbane acquired 100,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were acquired at an average price of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the acquisition, the director directly owned 1,904,186 shares of the company’s stock, valued at $2,799,153.42. This trade represents a 5.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Invus Global Management, Llc acquired 1,538,462 shares of the stock in a transaction dated Monday, February 2nd. The stock was acquired at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the transaction, the director owned 1,538,462 shares of the company’s stock, valued at approximately $2,000,000.60. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 1,790,462 shares of company stock valued at $2,369,981 over the last ninety days. 13.90% of the stock is owned by corporate insiders.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP purchased a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth about $26,000. Security National Bank of Sioux City Iowa IA purchased a new position in Lexicon Pharmaceuticals during the fourth quarter worth approximately $31,000. EntryPoint Capital LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $39,000. Virtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $42,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth $45,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Key Stories Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $6.00 and reiterated a Buy, signaling strong analyst conviction and large implied upside versus the current price. Higher analyst targets can attract buyers and support momentum. Street Insider: PT Raised to $6
• Positive Sentiment: Q4 results beat estimates: GAAP EPS of -$0.04 beat consensus and revenue of $5.49M topped forecasts, which reduces near‑term execution risk and supports the narrative of improving fundamentals. Earnings Beat
• Positive Sentiment: Clinical and corporate milestones announced: planned NDA resubmission for sotagliflozin in T1D, SONATA enrollment for HCM, positive End‑of‑Phase‑2 meeting for pilavapadin (supporting Phase 3 readiness), and ongoing partnership talks — all de‑risk future value catalysts. Press Release: Q4 Results & Clinical Updates
• Positive Sentiment: Balance sheet strengthened: management disclosed more than $100M in additional cash from a capital raise and a Novo Nordisk milestone payment, improving runway and reducing near‑term financing risk. Press Release: Cash Update
• Neutral Sentiment: Management commentary and full Q4 call transcript available for investors to assess execution details and timelines. Review the transcript/webcast for guidance nuances. Earnings Call Transcript
• Neutral Sentiment: Analyst model updates: HC Wainwright published FY2027/FY2028 EPS forecasts (-$0.21 and -$0.18) that are better than the current consensus (-$0.66 for the year), reflecting expectations of narrowing losses but still negative near‑term earnings. Analyst Estimates
• Negative Sentiment: Company remains unprofitable with a negative net margin (~96.8%) and negative ROE; earnings are expected to remain below zero in the near term—a structural risk that keeps the stock speculative. Earnings Detail

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on LXRX shares. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Finally, HC Wainwright increased their target price on Lexicon Pharmaceuticals from $4.00 to $6.00 and gave the company a “buy” rating in a report on Thursday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Lexicon Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $4.63.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.